These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 34534136)

  • 1. Clinicopathologic Analysis of Primary Adrenal Diffuse Large B-Cell Lymphoma: A Reappraisal of 23 Japanese Patients Based on EBV Association and PD-L1 Expression in Tumor Cells.
    Kawano T; Tsuyuki Y; Suzuki Y; Shimada K; Kato S; Takahara T; Mori M; Nakaguro M; Sakakibara A; Nakamura S; Satou A
    Am J Surg Pathol; 2021 Dec; 45(12):1606-1615. PubMed ID: 34534136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological analysis of primary intestinal diffuse large B-cell lymphoma: Prognostic evaluation of CD5, PD-L1, and Epstein-Barr virus on tumor cells.
    Ishikawa E; Kato S; Shimada K; Tanaka T; Suzuki Y; Satou A; Kohno K; Sakakibara A; Yamamura T; Nakamura M; Miyahara R; Goto H; Nakamura S; Hirooka Y
    Cancer Med; 2018 Dec; 7(12):6051-6063. PubMed ID: 30449068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological analysis of neoplastic PD-L1-positive EBV
    Takahara T; Satou A; Ishikawa E; Kohno K; Kato S; Suzuki Y; Takahashi E; Ohashi A; Asano N; Tsuzuki T; Nakamura S
    Virchows Arch; 2021 Mar; 478(3):541-552. PubMed ID: 32803453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reappraisal of Primary Epstein-Barr Virus (EBV)-positive Diffuse Large B-Cell Lymphoma of the Gastrointestinal Tract: Comparative Analysis Among Immunosuppressed and Nonimmunosuppressed Stage I and II-IV Patients.
    Miyagi S; Ishikawa E; Nakamura M; Shimada K; Yamamura T; Furukawa K; Tanaka T; Mabuchi S; Tsuyuki Y; Kohno K; Sakakibara A; Satou A; Kato S; Fujishiro M; Nakamura S
    Am J Surg Pathol; 2020 Sep; 44(9):1173-1183. PubMed ID: 32349049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epstein-Barr virus (EBV) positive diffuse large B cell lymphoma of the elderly-experience of a single center from Turkey.
    Ozsan N; Cagirgan S; Saydam G; Gunes A; Hekimgil M
    Pathol Res Pract; 2013 Aug; 209(8):471-8. PubMed ID: 23726928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical impact of serum survivin positivity and tissue expression of EBV-encoded RNA in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
    Hong JY; Ryu KJ; Park C; Hong M; Ko YH; Kim WS; Kim SJ
    Oncotarget; 2017 Feb; 8(8):13782-13791. PubMed ID: 28099151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Programmed cell death-ligand 1 (PD-L1)
    Kimura S; Oshiro Y; Iwasaki H; Kadowaki M; Mihashi Y; Sakata T; Kawauchi S; Wang Z; Takamatsu Y; Takeshita M
    Clin Exp Med; 2022 Aug; 22(3):411-419. PubMed ID: 34515880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EBV-positive diffuse large B-cell lymphoma features PD-L1 protein but not mRNA overexpression.
    Xue T; Wang WG; Zhou XY; Li XQ
    Pathology; 2018 Dec; 50(7):725-729. PubMed ID: 30389217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of EBV-encoded small RNA targeted PCR to classify EBV positive diffuse large B-cell lymphoma (DLBCL) of the elderly.
    Lee J; Park M; Lee MH; Woo HJ; Kim HW; Yang JY; Eom YB; Kim SH; Yoo C; Kim JB
    Int J Clin Exp Pathol; 2015; 8(7):7859-68. PubMed ID: 26339350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological evaluation of the programmed cell death 1 (PD1)/programmed cell death-ligand 1 (PD-L1) axis in post-transplant lymphoproliferative disorders: association with Epstein-Barr virus, PD-L1 copy number alterations, and outcome.
    Veloza L; Teixido C; Castrejon N; Climent F; Carrió A; Marginet M; Soldini D; González-Farré B; Ribera-Cortada I; Lopez-Guillermo A; González-Barca E; Sierra A; Herrera M; Gómez C; Garcia A; Balagué O; Campo E; Martinez A
    Histopathology; 2019 Dec; 75(6):799-812. PubMed ID: 30861172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma.
    Park S; Lee J; Ko YH; Han A; Jun HJ; Lee SC; Hwang IG; Park YH; Ahn JS; Jung CW; Kim K; Ahn YC; Kang WK; Park K; Kim WS
    Blood; 2007 Aug; 110(3):972-8. PubMed ID: 17400912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Significance of
    Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
    Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
    [No Abstract]   [Full Text] [Related]  

  • 13. Epstein-Barr Virus-Positive Diffuse Large B cell Lymphoma in the Experience of a Tertiary Medical Center in Poland.
    Ziarkiewicz M; Wołosz D; Dzieciątkowski T; Wilczek E; Dwilewicz-Trojaczek J; Jędrzejczak WW; Gierej B; Ziarkiewicz-Wróblewska B
    Arch Immunol Ther Exp (Warsz); 2016 Apr; 64(2):159-69. PubMed ID: 26084760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of co-inhibitory molecules B7-H4 and B7-H1 in Epstein-Barr virus positive diffuse large B-cell lymphoma and their roles in tumor invasion.
    Jiang Y; Lin J; Zhang J; Lu S; Wang C; Tong Y
    Pathol Res Pract; 2019 Dec; 215(12):152684. PubMed ID: 31679792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High PTX3 expression is associated with a poor prognosis in diffuse large B-cell lymphoma.
    Carreras J; Kikuti YY; Hiraiwa S; Miyaoka M; Tomita S; Ikoma H; Ito A; Kondo Y; Itoh J; Roncador G; Martinez A; Colomo L; Hamoudi R; Ando K; Nakamura N
    Cancer Sci; 2022 Jan; 113(1):334-348. PubMed ID: 34706126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic significance of EBV DNA load and EBER status in diagnostic specimens from diffuse large B-cell lymphoma patients.
    Okamoto A; Yanada M; Inaguma Y; Tokuda M; Morishima S; Kanie T; Yamamoto Y; Mizuta S; Akatsuka Y; Yoshikawa T; Mizoguchi Y; Nakamura S; Okamoto M; Emi N
    Hematol Oncol; 2017 Mar; 35(1):87-93. PubMed ID: 26177728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disparity analysis and prognostic value of pretreatment whole blood Epstein-Barr virus DNA load and Epstein-Barr encoding region status in lymphomas: A retrospective multicenter study in Huaihai Lymphoma Working Group.
    Shen Z; Hu L; Yao M; He C; Liu Q; Wang F; Gu W; Wang Y; Dong M; Zhu T; Yin T; Li F; Jin Y; Huang S; Zhang H; Sang W;
    Int J Cancer; 2022 Jan; 150(2):327-334. PubMed ID: 34520566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epstein Barr Virus Infection Can be a Secondary Event in B-Cell Lymphomas: A Review of 338 Cases and a Novel Finding of Zonal EBER+ Tumor Cells Showing Features of Progression From Underlying EBV-negative Lymphoma.
    Miller IJ
    Appl Immunohistochem Mol Morphol; 2019 Mar; 27(3):165-173. PubMed ID: 28800008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TET2 and LILRB1 mutations are frequent in Epstein-Barr virus-positive diffuse large B-cell lymphoma especially in elderly patients.
    Cho J; Kim E; Yoon SE; Kim SJ; Kim WS
    Cancer; 2023 May; 129(10):1502-1512. PubMed ID: 36812290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications.
    Xing W; Dresser K; Zhang R; Evens AM; Yu H; Woda BA; Chen BJ
    Oncotarget; 2016 Sep; 7(37):59976-59986. PubMed ID: 27527850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.